Skip to content Skip to footer

About Us

PROVIREX Genome Editing Therapies GmbH is a pioneering biotech company dedicated to developing groundbreaking genome editing therapies for the cure of HIV. Our core technology harnesses highly specific designer recombinases—such as Brec1—to precisely remove integrated HIV DNA from infected cells. Unlike conventional gene editing methods, our recombinase-based approach achieves exceptional accuracy and safety by directly excising viral genomes without relying on cellular DNA repair mechanisms.

At our unique therapy hub in Hamburg, we operate Europe’s only S3** biosafety cleanrooms specifically designed for advanced therapy medicinal product (ATMP) manufacturing. This integrated facility sets new standards for safety and quality, enabling the development and clinical application of innovative, personalized HIV therapies. Our passionate team combines scientific excellence and innovative spirit to transform the future of HIV therapy.

TECHNOLOGY

Technology

Stay up-to-date

Latest News

New Article in Biopharma Dealmakers Highlights Our HIV Cure Strategy
We are excited to announce the publication of a new article in Biopharma Dealmakers, a magazine by Springer Nature, featuring our innovative approach to achieving a functional cure for HIV. The article provides an in-depth assessment of our scientific strategy, the underlying technology platform, and the…
CEO Announcement
We are delighted to announce that Dr. Jan-Uwe Claas is joining PROVIREX from March 1st onwards as our new Chief Executive Officer and as Partner of PROVIREX. With over 25 years of comprehensive experience in the biotech and pharmaceutical industries, Dr. Claas brings a wealth…
Next scientific publication is online!
Our new scientific publication is now published in Plos One. In this publication we present an extensive preclinical evaluation of our Brec1 technology and lentiviral vectors expressing the Brec1 transgene. This included detailed functional analysis of potential genomic off-target sites, assessing vector safety by investigating…